Springfield, New Jersey - Evergreen Theragnostics, a US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), is pleased to announce that it has raised $15 million in a Series B funding round. The financing was led by some prominent investors and was supported by the company’s founder James Cook.

Founded in 2019, Evergreen Theragnostics has established itself as an industry leader in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management. This strategic injection of capital will allow the company to accelerate its research and development efforts while expanding its operations globally. 

Commenting on the successful fundraising, James Cook stated: “This investment will enable us to continue our mission of providing customers with high-quality radiopharmaceutical products at competitive prices. We are excited about the possibilities this funding round brings and are confident that it will help us expand our customer base and extend our reach across the globe."

With this new investment, Evergreen Theragnostics is poised to make significant strides toward achieving its goal of becoming one of the leading CDMOs in the pharmaceutical manufacturing industry.